VivoSeq
Infectious Disease

Cytomegalovirus Infection

32

Pipeline Programs↗

13

Active Trials↗

18

Companies Involved↗

Cytomegalovirus Infection is a moderately active landscape with 32 programs across 18 companies. The most active players are Pfizer, Iovance Biotherapeutics, Inc., Eastern Cooperative Oncology Group. 11 therapies are approved with 6 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

55/100

Pipeline Velocity

15/100

Mech. Concentration

43/100

Completion Rate

90/100

Attrition Rate

5/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Pfizer logo

Pfizer

1 program

Phase 1I

Iovance Biotherapeutics, Inc.

1 program

Phase 1E

Eastern Cooperative Oncology Group

1 program

Phase 1N

Nobelpharma

1 program

Phase 2G

Genzyme, a Sanofi Company

1 program

Phase 2Emergent BioSolutions logo

Emergent BioSolutions

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical1

Standard Intravenous Immunoglobulin

Fondazione Onlus Camillo De Lellis

Phase 15

Dextromethorphan

Pfizer

Aldesleukin

Iovance Biotherapeutics, Inc.

Therapeutic Allogeneic Lymphocytes

Eastern Cooperative Oncology Group

Tetanus-CMV Fusion Peptide Vaccine

City of Hope Medical Center

CMV Specific Adoptive T-Cells

Mari Dallas

Phase 29

Foscarnet Sodium

National Institute of Allergy and Infectious Diseases (NIAID)

Alemtuzumab

Genzyme, a Sanofi Company

MF-59

National Institute of Allergy and Infectious Diseases (NIAID)

Brincidofovir

Emergent BioSolutions

Adoptive Immunotherapy

M.D. Anderson Cancer Center

Phase 36

Valacyclovir

Glaxo Dba Glaxosmithkline

Acyclovir

Bp Consulting, Inc

Ganciclovir

Exela Pharma Sciences, LLC.

Maribavir

Takeda

ROVALCYTE

University Hospital, Rouen

Approved11

Valganciclovir

Engelhard Arzneimittel GmbH & Co.KG

Adefovir Dipivoxil

Gilead

Letermovir

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Cidofovir

Gilead

Artesunate

Amivas Inc.

Analysis

Modality Breakdown

70%

Small molecule

23 of 33 classified programs — the dominant modality here.

30%ALL OTHERSCell therapy412%Vaccine39%Monoclonal antibody26%Protein / enzyme13%

Small molecule leads; the ring shows all 33 classified programs, each share of the total. Modality classified for 100% of 38 pipeline programs.

Analysis

Trial Status

40

clinical trials

Completed18 · 45%
Recruiting9 · 23%
Unknown status7 · 18%
Not yet recruiting3 · 8%
Active, not recruiting1 · 3%
Withdrawn1 · 3%
Other1 · 3%

Clinical Trials

Trial Activity

40 trials

Effectiveness of an Immune-guided Cytomegalovirus Infection Preventive Strategy Compared to a Universal Prophylactic Strategy in Renal Transplant Patients
Recruiting·UUniversity Hospital, Rouen·Phase 3·NCT05708508·144 enrolled
Efficacy and Safety of Leymovir Versus Valganciclovir in Prevention of Cytomegalovirus Infection and Cytomegalovirus Disease in Chinese Kidney Transplant Recipients
Recruiting·FFirst Affiliated Hospital Xi'an Jiaotong University·Phase 4·NCT07266467·290 enrolled
Prophylaxis of Cytomegalovirus Infection With Adoptive Cell Inmunotherapy
Recruiting·IInstituto de Investigación Marqués de Valdecilla·Phase 2·NCT04056533·15 enrolled
A Study of the Drug Letermovir as Prevention of Cytomegalovirus Infection After Stem Cell Transplant in Pediatric Patients
Recruiting·Children's Oncology Group·Phase 3·NCT05711667·105 enrolled
T Cell Therapy of Opportunistic Cytomegalovirus Infection
Recruiting·—·Phase 1·NCT02982902·20 enrolled
A Survey of Maribavir Tablets in Participants With Cytomegalovirus Infection
Recruiting·Takeda logoTakeda·N/A·NCT06577363·250 enrolled
Combination Letermovir and Standard of Care Antiviral for Enhanced Antiviral Response in Cytomegalovirus Infection in Lung Transplant Recipients
Recruiting·UUniversity Health Network, Toronto·Phase 4·NCT07235683·40 enrolled
Letermovir-based Dual Therapy for Treatment of Cytomegalovirus Infections
Recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT06334497·80 enrolled
Prenatal Treatment of Congenital Cytomegalovirus Infection with Letermovir Versus Valaciclovir
Recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT05446571·46 enrolled
Donor Cytomegalovirus-Specific Cytotoxic T-Lymphocytes in Treating Patients With a Persistent Cytomegalovirus Infection
Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT02210078·49 enrolled
Evaluation of Long-term Efficacy of 4 to 6-month Course Antiviral Therapy for Neurodevelopmental Impairments Caused by Congenital Cytomegalovirus Infection
Not yet recruiting·—·Phase 4·NCT07450365·150 enrolled
A Prospective Single-Arm Observational Study of Maribavir for the Treatment of Post Hematopoietic Stem Cell Transplantation Cytomegalovirus Infection
Not yet recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·N/A·NCT07141095·17 enrolled
Evaluation of the Prophylactic Use of Letermovir in Kidney Transplant Recipients at Risk of Cytomegalovirus Infection
Not yet recruiting·HHospital do Rim e Hipertensão·Phase 3·NCT06341686·100 enrolled
A Pharmacokinetic and Tolerance Study of Oral Ganciclovir in HIV-Infected Children With Asymptomatic Cytomegalovirus Infection and Low CD4 Cell Counts or Quiescent Cytomegalovirus Disease
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000805·32 enrolled
A Study of Maribavir Compared to Valganciclovir to Treat Cytomegalovirus Infections in People Who Have Received Stem Cell Transplants
Completed·Takeda logoTakeda·Phase 3·NCT02927067·553 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)